DDInter721 DDInter1678
An anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Fenoprofen {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Fenoprofen {u} (Compound) resembles {v} (Compound) Modafinil
Modafinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Fenoprofen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Fenoprofen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Fenoprofen {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Fenoprofen {u} (Compound) causes {v} (Side Effect) Nephrotic syndrome
Nephrotic syndrome {u} (Side Effect) is caused by {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Fenoprofen {u} (Compound) resembles {v} (Compound) Modafinil
Modafinil {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Sirolimus
Fenoprofen {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) downregulates {v} (Gene) S100A13
S100A13 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Fenoprofen {u} (Compound) resembles {v} (Compound) Fenbufen
Fenbufen {u} (Compound) resembles {v} (Compound) Ketorolac
Ketorolac {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Fenoprofen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} (Compound) upregulates {v} (Gene) CNPY3
CNPY3 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Fenoprofen (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Fenoprofen (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Fenoprofen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may lead to a major life threatening interaction when taken with Sirolimus
Fenoprofen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may lead to a major life threatening interaction when taken with Sirolimus
Fenoprofen (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Sirolimus (Compound)
Fenoprofen (Compound) causes Nephrotic syndrome (Side Effect) and Nephrotic syndrome (Side Effect) is caused by Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Fenoprofen (Compound) resembles Modafinil (Compound) and Modafinil (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Sirolimus (Compound)
Fenoprofen (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) downregulates S100A13 (Gene) and S100A13 (Gene) is upregulated by Sirolimus (Compound)
Fenoprofen (Compound) resembles Fenbufen (Compound) and Fenbufen (Compound) resembles Ketorolac (Compound) and Ketorolac may lead to a major life threatening interaction when taken with Sirolimus
Fenoprofen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen (Compound) upregulates CNPY3 (Gene) and CNPY3 (Gene) is upregulated by Sirolimus (Compound)